Takeda Pharmaceutical Company Limited

The Rockefeller University

Scohia Pharma, Inc.

Jumpei Aida

Satoshi Yamamoto

Hideyuki Sugiyama

Minoru Nakamura

Hidekazu Tokuhara

Yuya Oguro

Tomohiro Okawa

Masataka Murakami

Shuhei Ikeda

Koji Watanabe

Makoto Kamata

Norihito Tokunaga

Kazuaki Takami

Nobuyuki Takakura

Tsuyoshi Maekawa

Shigemitsu Matsumoto

Hideki Furukawa

Shizuo Kasai

Yasufumi Miyamoto

Taku Kamei

Yasuhiro Hirata

Seiji Miwatashi

Yuko Hitomi

Naoyoshi Noguchi

Shinji Nakamura

Tatsuki Koike

Masaki Seto

Keiko Kakegawa

Masaki Daini

Minoru Yoshida

Satoshi Mikami

Mitsuhiro Ito

Shinji Morimoto

Toshitake Kobayashi

Akito Shibuya

Kouichi Iwanaga

Makoto Fushimi

Hideyuki Igawa

Takeshi Wakabayashi

Tomokazu Kusumoto

Yasufumi Wada

Taisuke Tawaraishi

Yayoi Nakayama

Sachie Takashima

Hiroyuki Kakei

Yasushi Hattori

Thomas Tuschl

Satoshi Sasaki

Toshihiro Imaeda

Yasutomi Asano

Rei Okamoto

Asato Kina

Dinshaw J Patel

Minoru Ikoma

Mrinalkanti Kundu

Mayako Michino

Yayoi Yoshitomi

Lodoe Lama

J Fraser Glickman

Takanobu Kuroita

Michael Miller

Daisuke Tomita

Shogo Hashizume

Masako Miyazaki

Uttam Khamrai

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Heterocyclic compound and use thereof

1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.

Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): 

Heterocyclic compound

The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification,or a salt thereof.

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

Benzimidazole derivatives as MCH receptor antagonists

Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Jumpei Aida